Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab dose-ranging trial in moderate-to-severe atopic dermatitis
jRCT2080224747Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tezepelumab in atopic dermatitis (AD) (5 arms), sponsored by Amgen. Started Jun 2019; status: terminated.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224747.